SGLT2 inhibitors less commonly used in HFrEF patients despite possible CV benefits: JAMA.

Published Date: 26 May 2023

The use of SGLT2 inhibitors for HFrEF (heart failure with reduced ejection fraction) is uncommon in the United States, according to a recent study published in JAMA Cardiology.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Common intracellular toxin could help fight leukemia

2.

CAR T-Cell Therapy Shows Promise in Mantle Cell Lymphoma

3.

Scholastic performance is a key concern for young cancer patients, study finds

4.

AACR: American Association for Cancer Research

5.

Lung Cancer Screening Rates in Eligible Adults Remain Low, Uneven


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot